Search hospitals > Ohio > Toledo
Mercy Health - Saint Anne Hospital
Claim this profileToledo, Ohio 43623
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Tumors
263 reported clinical trials
2 medical researchers
Summary
Mercy Health - Saint Anne Hospital is a medical facility located in Toledo, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Tumors and other specialties. Mercy Health - Saint Anne Hospital is involved with conducting 263 clinical trials across 370 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and REX MOWAT, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
REX MOWAT, MDToledo Clinic Cancer Centers-Toledo4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
79 reported clinical trials
151 drugs studied
Clinical Trials running at Mercy Health - Saint Anne Hospital
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Melanoma
Cutaneous Melanoma
Tumors
Small Cell Lung Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Mercy Health - Saint Anne Hospital?
Mercy Health - Saint Anne Hospital is a medical facility located in Toledo, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Tumors and other specialties. Mercy Health - Saint Anne Hospital is involved with conducting 263 clinical trials across 370 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and REX MOWAT, MD.